Skip to content
Loading…
Bambusa Therapeutics Inc. shares slipped 7% in its trading debut after the early-stage biotech focused on dermatology and autoimmune diseases raised $168.9 million in a US initial public offering.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.